Sigma’s lentiviral technology will be coupled with SwitchGear’s GoClone miRNA target sets.

Sigma Life Science and SwitchGear Genomics signed a deal to develop and distribute an miRNA target reporter system.

Use of Sigma’s patented lentiviral technology is expected to allow the SwitchGear GoClone™ miRNA target sets to be used in a range of cell types including primary cells and stem cells.

“We believe that combining unique technologies from SwitchGear Genomics with Sigma’s industry-leading lentiviral technology and production capabilities will enable researchers to study miRNA function and gene regulation on an unprecedented scale,” says Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics.

Previous articleCapgemini to Offer Cegedim Dendrite’s Software Solutions
Next articleEndo to Acquire Penwest in Deal with Enterprise Value of $144M